| Literature DB >> 27625918 |
Stephan von Haehling1, Nicole Ebner1, Stefan D Anker1.
Abstract
Entities:
Year: 2016 PMID: 27625918 PMCID: PMC5011813 DOI: 10.1002/jcsm.12142
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Top ten journals in the field ‘Medicine: General & Internal’, adapted from reference 1
| Journal name | Impact factor 2016 | Items published in 2014 & 2015 | |
|---|---|---|---|
| 1 | New England journal of medicine | 59.558 | 701 |
| 2 | Lancet | 44.002 | 547 |
| 3 | Journal of the American medical association (JAMA) | 37.684 | 449 |
| 4 | British medical journal | 19.697 | 519 |
| 5 | Annals of internal medicine | 16.440 | 325 |
| 6 | JAMA internal medicine | 14.000 | 332 |
| 7 | PLOS medicine | 13.585 | 246 |
| 8 | BMC medicine | 8.005 | 379 |
| 9 | Jounal of cachexia sarcopenia and muscle | 7.883 | 60 |
| 10 | Journal of internal medicine | 7.803 | 198 |
Top ten journals in the field ‘Nutrition & Dietetics’, where the journal of cachexia, sarcopenia and muscle is officially not listed
| Journal name | Impact factor 2016 |
Items published | |
|---|---|---|---|
| 1 | Progress in lipid research | 11.238 | 63 |
| 2 | Annuals review of nutrition | 6.784 | 37 |
| 3 | American journal of clinical nutrition | 6.703 | 671 |
| 4 | Nutrition reviews | 5.591 | 149 |
| 5 | Critical reviews in food science and nutrition | 5.492 | 185 |
| 6 | International journal of obesity | 5.337 | 484 |
| 7 | Proceedings of the nutrition society | 4.703 | 111 |
| 8 | Journal of nutritional biochemistry | 4.668 | 398 |
| 9 | Advances in nutrition | 4.576 | 158 |
| 10 | Clinical nutrition | 4.487 | 318 |
Figure 1Number of manuscript submissions to the Journal of Cachexia, Sarcopenia and Muscle by year of publication. *Numbers for 2016 are estimated on the number of submissions until 18 July 2016 (Reprinted from 51).
Top twenty of best cited articles since first publication of the journal of cachexia, sarcopenia and muscle
| First author | Title | Type | Year | Times cited | Reference | |
|---|---|---|---|---|---|---|
| 1. | von Haehling | Cachexia as a major underestimated and unmet medical need: facts and numbers | Editorial | 2010 | 181 | 2 |
| 2. | von Haehling | An overview of sarcopenia: facts and numbers on prevalence and clinical impact | Editorial | 2010 | 94 | 3 |
| 3. | Dalton | The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial | Original Article | 2011 | 88 | 4 |
| 4. | Lenk | Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training | Review | 2010 | 86 | 5 |
| 5. | Mak | Wasting in chronic kidney disease | Review | 2011 | 66 | 6 |
| 6. | Fanzani | Molecular and cellular mechanisms of skeletal muscle atrophy: an update | Review | 2012 | 63 | 7 |
| 7. | Elkina | The role of myostatin in muscle wasting: an overview. | Review | 2011 | 63 | 8 |
| 8. | Cesari | Biomarkers of sarcopenia in clinical trials‐recommendations from the International Working Group on Sarcopenia | Original Article | 2012 | 60 | 9 |
| 9. | Lainscak | Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease | Original Article | 2011 | 55 | 10 |
| 10. | Morley | From sarcopenia to frailty: a road less traveled | Editorial | 2014 | 54 | 11 |
| 11. | von Haehling | From muscle wasting to sarcopenia and myopenia: update 2012 | Editorial | 2012 | 52 | 12 |
| 12. | Lainscak | The obesity paradox in chronic disease: facts and numbers | Editorial | 2012 | 44 | 13 |
| 13. | Patel | Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross‐sectional study and review of literature | Review | 2013 | 43 | 14 |
| 14. | Fearon | Myopenia‐a new universal term for muscle wasting | Editorial | 2011 | 43 | 15 |
| 15. | Sakuma | Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass | Review | 2012 | 42 | 16 |
| 16. | Schefold | Intensive care unit‐acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock | Review | 2010 | 41 | 17 |
| 17. | Busquets | Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance | Original Article | 2012 | 39 | 18 |
| 18. | Wakabayashi | Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management | Review | 2014 | 37 | 19 |
| 19. | Farkas | Cachexia as a major public health problem: frequent, costly, and deadly | Review | 2013 | 37 | 20 |
| 20. | Rozentryt | The effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot study | Original Article | 2010 | 35 | 21 |
Top twenty of best cited articles published 2014 in the journal of cachexia, sarcopenia and muscle
| First author | Title | Type | Year | Times cited | Reference | |
|---|---|---|---|---|---|---|
| 1. | Morley | From sarcopenia to frailty: a road less traveled | Editorial | 2014 | 54 | 11 |
| 2. | Wakabayashi | Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management | Review | 2014 | 37 | 19 |
| 3. | von Haehling | Prevalence, incidence and clinical impact of cachexia: facts and numbers‐update 2014 | Editorial | 2014 | 29 | 22 |
| 4. | Morley | Are we closer to having drugs to treat muscle wasting disease? | Editorial | 2014 | 26 | 23 |
| 5. | Anker | Muscle wasting disease: a proposal for a new disease classification | Editorial | 2014 | 24 | 24 |
| 6. | Ebner | Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies | Meeting Report | 2014 | 23 | 25 |
| 7. | Heymsfield | Assessing skeletal muscle mass: historical overview and state of the art | Review | 2014 | 21 | 26 |
| 8. | Pietra | Anamorelin HCI (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile | Original Article | 2014 | 20 | 27 |
| 9. | Morley | Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology‐update 2014 | Editorial | 2014 | 17 | 28 |
| 10. | Fragala | Biomarkers of muscle quality: N‐terminal propeptide of type III procollagen and C‐terminal agrin fragment responses to resistance exercise training in older adults | Original Article | 2014 | 15 | 29 |
| 11. | Toledo | Formoterol in the treatment of experimental cancer cachexia: effects on heart function | Original Article | 2014 | 13 | 30 |
| 12. | Rhee | Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? | Editorial | 2014 | 12 | 31 |
| 13. | Argiles | Cachexia: a problem of energetic inefficiency | Review | 2014 | 11 | 32 |
| 14. | Poetsch | The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats | Original Article | 2014 | 11 | 33 |
| 15. | Henwood | Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility | Original Article | 2014 | 10 | 34 |
| 16. | Ormsbee | Osteosarcopenic obesity: the role of bone, muscle, and fat on health | Review | 2014 | 10 | 35 |
| 17. | Alchin | Sarcopenia: describing rather than defining a condition | Review | 2014 | 9 | 36 |
| 18. | Mirza | Attenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin‐3‐gallate | Original Article | 2014 | 9 | 37 |
| 19. | Kirkman | Anabolic exercise in haemodialysis patients: a randomised controlled pilot study | Original Article | 2014 | 8 | 38 |
| 20. | Palus | Muscle wasting: an overview of recent developments in basic research | Review | 2014 | 8 | 39 |
Top ten of the best cited articles published 2015 in the journal of cachexia, sarcopenia and muscle
| First author | Title | Type | Year | Times cited | Reference | |
|---|---|---|---|---|---|---|
| 1. | Chen | Ghrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involved | Original Article | 2015 | 7 | 40 |
| 2. | Sasso | A framework for prescription in exercise‐oncology research | Editorial | 2015 | 6 | 41 |
| 3. | Stephens | Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients | Original Article | 2015 | 6 | 42 |
| 4. | Calvani | Biomarkers for physical frailty and sarcopenia: state of the science and future developments | Review | 2015 | 4 | 43 |
| 5. | Ezeoke | Pathophysiology of anorexia in the cancer cachexia syndrom | Review | 2015 | 4 | 44 |
| 6. | Fearon | Request for regulatory guidance for cancer cachexia intervention trials | Editorial | 2015 | 4 | 45 |
| 7 | Morley | Rapid screening for sarcopenia | Editorial | 2015 | 3 | 46 |
| 8. | Browen | Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training | Review | 2015 | 4 | 47 |
| 9. | Faber | Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junction | Original Article | 2015 | 4 | 48 |
| 10. | Trobec | Influence of cancer cachexia on drug liver metabolism and renal elimination in rats | Original Article | 2015 | 4 | 49 |